Sinovac Biotech Ltd. Begins Pandemic Flu (H5N1) Vaccine Clinical Trials

21 Dec, 2005, 00:00 ET from Sinovac Biotech Ltd.

    BEIJING, China, Dec. 21 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd.
 (Sinovac) (AMEX:   SVA - News) announced today it has initiated human clinical
 trials for its pandemic flu (H5N1) vaccine Panflu(TM). The vaccine was
 administered to the first 6 volunteers at the Beijing Sino-Japan Friendship
 Hospital in Beijing, China.
     Due to this vaccine's mature technology, China's State Food and Drug
 Administration (SFDA) earlier approved modification to "fast-track" the
 clinical trial process from 3 phases to only 2 stages.  Stage I includes 120
 healthy volunteers, ages 18 - 60 years and is expected to take nine-months.
 However, preliminary results should be available by the end of March, 2006.
     Sinovac CEO and Director, Mr. Weidong Yin commented, "This is a great day
 for us as we simultaneously advance China's National Pandemic Preparedness
 Plan and our corporate growth strategy. In addition to our successful R&D
 program, Sinovac has introduced two new vaccines into the market this year.
 Our national and international name recognition is expanding, and I expect
 tremendous revenue growth in 2006."
     Sinovac partnered with Beijing Sino-Japan Friendship Hospital for the
 successful Phase I SARS clinical trials in 2004. Protocols for clinical trials
 are strictly regulated and include compliance with SFDA's National Institute
 for the Control of Pharmaceutical and Biological Products (NICPBP), World
 Health Organization (WHO) "Guidelines on Clinical Evaluation of Vaccines," and
 other relevant regulations.  The trials will be compliant with Good Clinical
 Practices (GCP) procedures, including ethical guidelines.
     Sinovac's Deputy General Manager, Mr. Zhang Jiansan stated, "we have
 established an excellent reputation at Sinovac and maintain disciplined, safe
 procedures during all of our R&D and production functions."  These trials will
 use Sinovac's proprietary pandemic vaccine, Panflu(TM), which is an al
 adjuvant, whole virion type. Sinovac has produced sufficient vaccines to
 complete human clinical trials.  If clinical trials are successful, the
 Company estimates production capacity may be as high as 20 million doses per
 year using its current manufacturing facilities.
 
     About Sinovac
     Sinovac Biotech Ltd. is a world leader in the research, development,
 manufacture and commercialization of vaccines for endemic and pandemic viruses
 such as hepatitis and influenza, and for fast emerging viruses such as SARS
 and avian influenza (bird flu). The Company's objective is to provide Chinese
 children with the best vaccines in the world, and let children in the world
 use vaccines made in China.
     Additional information about Sinovac is available on the Company website,
 http://www.sinovac.com
     For additional information, investor newsletters and corporate updates,
 please email your request to: info@sinovac.com
 
     THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE
 MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS
 AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF
 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING
 ADDITIONAL PROJECT INTERESTS, SINOVAC'S ANALYSIS OF OPPORTUNITIES IN THE
 ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER
 MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE
 UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE
 RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY
 FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
 
 

SOURCE Sinovac Biotech Ltd.
    BEIJING, China, Dec. 21 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd.
 (Sinovac) (AMEX:   SVA - News) announced today it has initiated human clinical
 trials for its pandemic flu (H5N1) vaccine Panflu(TM). The vaccine was
 administered to the first 6 volunteers at the Beijing Sino-Japan Friendship
 Hospital in Beijing, China.
     Due to this vaccine's mature technology, China's State Food and Drug
 Administration (SFDA) earlier approved modification to "fast-track" the
 clinical trial process from 3 phases to only 2 stages.  Stage I includes 120
 healthy volunteers, ages 18 - 60 years and is expected to take nine-months.
 However, preliminary results should be available by the end of March, 2006.
     Sinovac CEO and Director, Mr. Weidong Yin commented, "This is a great day
 for us as we simultaneously advance China's National Pandemic Preparedness
 Plan and our corporate growth strategy. In addition to our successful R&D
 program, Sinovac has introduced two new vaccines into the market this year.
 Our national and international name recognition is expanding, and I expect
 tremendous revenue growth in 2006."
     Sinovac partnered with Beijing Sino-Japan Friendship Hospital for the
 successful Phase I SARS clinical trials in 2004. Protocols for clinical trials
 are strictly regulated and include compliance with SFDA's National Institute
 for the Control of Pharmaceutical and Biological Products (NICPBP), World
 Health Organization (WHO) "Guidelines on Clinical Evaluation of Vaccines," and
 other relevant regulations.  The trials will be compliant with Good Clinical
 Practices (GCP) procedures, including ethical guidelines.
     Sinovac's Deputy General Manager, Mr. Zhang Jiansan stated, "we have
 established an excellent reputation at Sinovac and maintain disciplined, safe
 procedures during all of our R&D and production functions."  These trials will
 use Sinovac's proprietary pandemic vaccine, Panflu(TM), which is an al
 adjuvant, whole virion type. Sinovac has produced sufficient vaccines to
 complete human clinical trials.  If clinical trials are successful, the
 Company estimates production capacity may be as high as 20 million doses per
 year using its current manufacturing facilities.
 
     About Sinovac
     Sinovac Biotech Ltd. is a world leader in the research, development,
 manufacture and commercialization of vaccines for endemic and pandemic viruses
 such as hepatitis and influenza, and for fast emerging viruses such as SARS
 and avian influenza (bird flu). The Company's objective is to provide Chinese
 children with the best vaccines in the world, and let children in the world
 use vaccines made in China.
     Additional information about Sinovac is available on the Company website,
 http://www.sinovac.com
     For additional information, investor newsletters and corporate updates,
 please email your request to: info@sinovac.com
 
     THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE
 MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS
 AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF
 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING
 ADDITIONAL PROJECT INTERESTS, SINOVAC'S ANALYSIS OF OPPORTUNITIES IN THE
 ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER
 MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE
 UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE
 RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY
 FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
 
 SOURCE  Sinovac Biotech Ltd.